Cencora, Inc. $COR Shares Acquired by Fulcrum Asset Management LLP

Fulcrum Asset Management LLP increased its position in shares of Cencora, Inc. (NYSE:COR) by 152.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 130,835 shares of the company’s stock after acquiring an additional 79,087 shares during the quarter. Cencora comprises approximately 1.8% of Fulcrum Asset Management LLP’s investment portfolio, making the stock its 5th biggest holding. Fulcrum Asset Management LLP’s holdings in Cencora were worth $40,245,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Elevation Wealth Partners LLC increased its stake in Cencora by 506.2% in the second quarter. Elevation Wealth Partners LLC now owns 97 shares of the company’s stock valued at $27,000 after purchasing an additional 81 shares in the last quarter. Bell Investment Advisors Inc acquired a new stake in Cencora in the second quarter worth $28,000. Caitlin John LLC bought a new position in shares of Cencora during the second quarter worth $28,000. Cassaday & Co Wealth Management LLC bought a new position in shares of Cencora during the first quarter worth $35,000. Finally, Lynch Investment Planning LLC bought a new position in shares of Cencora during the third quarter worth $39,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Activity

In related news, EVP Elizabeth Campbell sold 11,300 shares of the stock in a transaction dated Monday, August 24th. The stock was sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the completion of the transaction, the executive vice president directly owned 19,455 shares in the company, valued at approximately $6,305,754.60. This trade represents a 36.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.38% of the company’s stock.

Cencora Price Performance

Shares of NYSE COR opened at $333.38 on Monday. The company has a fifty day moving average price of $325.07 and a 200 day moving average price of $317.28. The firm has a market cap of $63.62 billion, a PE ratio of 18.60, a PEG ratio of 1.72 and a beta of 0.58. The company has a current ratio of 0.94, a quick ratio of 0.59 and a debt-to-equity ratio of 3.01. Cencora, Inc. has a 1-year low of $244.82 and a 1-year high of $377.54.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, November 4th. The company reported $4.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.58 by $0.08. Cencora had a return on equity of 110.72% and a net margin of 1.03%. The firm had revenue of $88.35 billion for the quarter, compared to the consensus estimate of $87.95 billion. During the same quarter last year, the business posted $3.84 EPS. The company’s revenue for the quarter was up 5.5% on a year-over-year basis. Research analysts predict that Cencora, Inc. will post 19.58 earnings per share for the current fiscal year.

Cencora Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 30th. Stockholders of record on Friday, November 13th will be given a dividend of $0.66 per share. This is an increase from Cencora’s previous quarterly dividend of $0.60. This represents a $2.64 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Friday, November 13th. Cencora’s payout ratio is currently 14.73%.

Key Headlines Impacting Cencora

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Cencora beat quarterly expectations, reporting EPS of $4.66 versus estimates of $4.58 and revenue of $88.35 billion versus $87.95 billion; revenue grew 5.5% year over year. The company also issued a stronger fiscal 2027 earnings outlook, reinforcing expectations for continued growth. Cencora stock enters fiscal 2027 with stronger earnings outlook
• Positive Sentiment: Leerink Partners raised its price target to $405 from $388 and maintained an “outperform” rating, signaling confidence in potential upside.
• Positive Sentiment: Cencora raised its dividend, adding to its appeal for income-focused investors amid market uncertainty. Stocks that hiked dividends
• Neutral Sentiment: The company is realigning its corporate structure. The available report headline does not specify the changes or their expected financial impact. Cencora realigning corporate structure
• Negative Sentiment: Despite Cencora’s earnings beat, shares came under pressure after rival Cardinal Health reported results, prompting concern about relative performance and contributing to a short-term pullback. Cencora drops while rival Cardinal Health posts a beat

Analysts Set New Price Targets

Several brokerages have recently issued reports on COR. Leerink Partners boosted their price target on shares of Cencora from $388.00 to $405.00 and gave the company an “outperform” rating in a report on Thursday. Citigroup reaffirmed a “buy” rating on shares of Cencora in a research note on Thursday, August 6th. Morgan Stanley lifted their target price on Cencora from $346.00 to $377.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Royal Bank Of Canada reiterated a “sector perform” rating and set a $330.00 target price on shares of Cencora in a report on Tuesday, September 8th. Finally, JPMorgan Chase & Co. boosted their target price on Cencora from $382.00 to $390.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Thirteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $368.73.

Cencora Profile

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical services company that connects pharmaceutical manufacturers with healthcare providers. Its core business includes sourcing and distributing medicines and other healthcare products to pharmacies, hospitals, health systems and other care providers.

The company also provides services supporting specialty pharmaceuticals, including logistics, consulting and solutions for manufacturers and healthcare organizations. These services help manage the handling and delivery of complex medicines and support access to treatments.

Cencora serves customers in the United States and internationally.